At canZero we are at the forefront of research and development of novel cancer therapeutics. We build on the fully licensed-in Self-Assembling-Protein-Nanoparticle (SAPN) technology. The SAPNs are a highly versatile platform that can be used for the design of vaccines as well as drug targeting and delivery vehicles. By combining these approaches, we engineer our proprietary VaccinoDrugs to deliver the most efficient new modalities of cancer treatment (learn more). ​

The SAPN approach has demonstrated high effectiveness in animal models and has significantly reduced the time from idea to product. For example, a SAPN-based COVID vaccine has shown to be immunologically as potent as Pfizer's mRNA vaccine in an animal mouse model. The SAPN technology has received $7.6 million NIH funding and has already gained FDA approval for a Phase/IIa clinical trial for a malaria vaccine. 

canZero is a registered company in Chicago, IL and the leadership team comprises Kamal ElBissati as the CEO, Chris Karch as the CSO, and Peter Burkhard as the President. They all have extensive experience in the biopharmaceutical industry, particularly in working with the SAPNs (learn more).